Stimulation of Antibody Following 51Chromium Survival Studies

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

6
Reader(s)
10
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 3 , ISSUE 1 (March 1987) > List of articles

Stimulation of Antibody Following 51Chromium Survival Studies

Susan S. Esty / Delores Mallory / Richard J. Davey / Tracy Wahl / Julie Zswisza

Citation Information : Immunohematology. Volume 3, Issue 1, Pages 6-8, DOI: https://doi.org/10.21307/immunohematology-2019-1119

License : (Transfer of Copyright)

Published Online: 31-December-2020

ARTICLE

ABSTRACT

The survival of red blood cells (RBCs) radiolabeled with 51chromium (51Cr) is a reliable method for predicting transfusion compatibility. Approximately 1.0 ml of 51Cr tagged RBCs is infused into the patient and samples are drawn at predetermined intervals post infusion to determine RBC survival. Red cells used for the study are usually incompatible with the patient's antibody. This antigenic rechallenge may stimulate further antibody production, which could contribute to accelerated destruction of RBCs during subsequent incompatible transfusions. To study this question, blood samples were collected from six patients with a single atypical alloantibody, seven to nine months after 51Cr RBC survival studies had been performed in an unrelated protocol. Blood had not been transfused in the interim. The samples were tested in parallel with pre-survival samples for change in antibody titer and score. In addition, RBCs used for the 51Cr survival study, sensitized in vitro with pre- and post-survival serum, were tested by the monocyte monolayer assay (MMA). Serum antibody titers showed a significant increase (>2 dilutions) in two of six patients and antibody score was significantly increased (>10) in three of six patients. One of the two negative MMAs became weakly positive. This study suggests that 51Cr survival tests using small volumes of RBCs can stimulate significant increases in antibody in some patients, a factor that must be considered in performing these tests and in planning subsequent transfusions.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share